J Rheum Dis 2017; 24(4): 220-226
Published online August 31, 2017
© Korean College of Rheumatology
Correspondence to : Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. E-mail:leb7616@snu.ac.kr
This is a Open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. Rheumatoid arthritis (RA) patients suffer from an increased risk of herpes zoster (HZ) partially due to immunosuppressant medications. This study investigated HZ in RA patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs), as compared with conventional DMARDs (cDMARDs). Methods. This retrospective case series study assembled record information of 277 RA patients who received bDMARDs after failure of at least one cDMARDs at Seoul National University Hospital between August 2003 and February 2015. Following capture of baseline information and identification of HZ episodes, crude HZ incidence rates per 100 patient-years (95% confidence intervals) were calculated. Results. For 718 treatment courses, 277 (38.6%) comprised cDMARDs, 66 (9.2%) infliximab, 175 (24.4%) etanercept, 95 (13.2%) adalimumab, 9 (1.3%) golimumab, 41 (5.7%) rituximab, 31 (4.3%) abatacept, and 24 (3.3%) tocilizumab. There were 37 HZ episodes, 16 during cDMARD treatment courses, and 21 accompanying bDMARDs, two with infliximab, eight with etanercept, five with adalimumab, and three each with rituximab and abatacept. The crude HZ incidence rate per 100 patient-years was 2.4 (1.4∼3.9) for cDMARDs, 2.2 (0.3∼7.9) for infliximab, 1.8 (0.8∼3.6) for etanercept, 3.7 (1.2∼8.4) for adalimumab, 3.9 (0.8∼11.0) for rituximab, and 8.5 (1.8∼23.1) for abatacept. Conclusion. We conclude that bDMARDs do not always increase the risk of HZs in RA patients, although HZ rates vary for different bDMARDs.
Keywords Herpes zoster, Rheumatoid arthritis, Biological therapies, Antirheumatic agents
J Rheum Dis 2017; 24(4): 220-226
Published online August 31, 2017 https://doi.org/10.4078/jrd.2017.24.4.220
Copyright © Korean College of Rheumatology.
Hyun Mi Kwon1*, Sang Jin Lee1*, Ji Ae Yang1, Yunhee Choi2, Jin Kyun Park1, Eun Young Lee1, Yeong Wook Song1, Eun Bong Lee1
1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, 2Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea
Correspondence to:Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. E-mail:leb7616@snu.ac.kr
This is a Open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. Rheumatoid arthritis (RA) patients suffer from an increased risk of herpes zoster (HZ) partially due to immunosuppressant medications. This study investigated HZ in RA patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs), as compared with conventional DMARDs (cDMARDs). Methods. This retrospective case series study assembled record information of 277 RA patients who received bDMARDs after failure of at least one cDMARDs at Seoul National University Hospital between August 2003 and February 2015. Following capture of baseline information and identification of HZ episodes, crude HZ incidence rates per 100 patient-years (95% confidence intervals) were calculated. Results. For 718 treatment courses, 277 (38.6%) comprised cDMARDs, 66 (9.2%) infliximab, 175 (24.4%) etanercept, 95 (13.2%) adalimumab, 9 (1.3%) golimumab, 41 (5.7%) rituximab, 31 (4.3%) abatacept, and 24 (3.3%) tocilizumab. There were 37 HZ episodes, 16 during cDMARD treatment courses, and 21 accompanying bDMARDs, two with infliximab, eight with etanercept, five with adalimumab, and three each with rituximab and abatacept. The crude HZ incidence rate per 100 patient-years was 2.4 (1.4∼3.9) for cDMARDs, 2.2 (0.3∼7.9) for infliximab, 1.8 (0.8∼3.6) for etanercept, 3.7 (1.2∼8.4) for adalimumab, 3.9 (0.8∼11.0) for rituximab, and 8.5 (1.8∼23.1) for abatacept. Conclusion. We conclude that bDMARDs do not always increase the risk of HZs in RA patients, although HZ rates vary for different bDMARDs.
Keywords: Herpes zoster, Rheumatoid arthritis, Biological therapies, Antirheumatic agents
Jung Hee Koh, M.D., Ph.D., Bong-Woo Lee, M.D., Wan-Uk Kim, M.D., Ph.D.
J Rheum Dis 2023; 30(4): 234-242Myeung-su Lee, M.D., Ph.D., Chang Hoon Lee, M.D., Ph.D., Hye Soon Lee, M.D., Ph.D., Yoon-Kyoung Sung, M.D., Ph.D., Jung Ran Choi, M.D., Ph.D., Kyungsu Park, M.D., Ph.D., Mi-Kyoung Lim, M.D., Ph.D., Byoong Yong Choi, M.D., Hyoun-Ah Kim, M.D., Ph.D., Seung Won Choi, M.D., Ph.D., Yusun Lee, M.D., Wan-Hee Yoo, M.D., Ph.D.
J Rheum Dis 2021; 28(2): 68-75Hyun Mi Kwon, Kichul Shin, Jin Young Moon, Shin-Seok Lee, Won Tae Chung, Jisoo Lee, Sang-Heon Lee, Seong-Wook Kang, Chang Hee Suh, Seung-Jae Hong, Ran Song, Jung-Yoon Choe, Yeong Wook Song
J Rheum Dis 2018; 25(2): 108-115